LENZ LENZ Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%
Returns
ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.38M | $5.49M | $1.90M | $1.59M | $12.50M | $5.00M | $0 | $0 |
| Cost of revenue | $454,000 | $280,000 | $1.08M | $418,000 | $0 | $0 | $0 | — |
| Gross profit | $2.93M | $5.21M | $825,000 | $1.17M | $12.50M | $5.00M | $0 | — |
| R&D expense | $0 | $0 | $0 | $0 | $3.79M | $9.06M | $5.82M | $5.87M |
| SG&A expense | $35.85M | $39.38M | $44.96M | $39.63M | $27.60M | $12.80M | $11.11M | $9.36M |
| Operating income | -$32.92M | -$34.17M | -$44.13M | -$38.46M | -$18.89M | -$16.86M | -$16.93M | -$15.22M |
| Pretax income | -$30.97M | -$31.91M | — | -$35.89M | -$16.70M | -$14.41M | — | -$12.65M |
| Income tax | $0 | $3,000 | — | $2,000 | $0 | $500,000 | — | $1,000 |
| Net income | -$30.97M | -$31.92M | -$41.49M | -$35.90M | -$16.70M | -$14.91M | -$14.62M | -$12.65M |
| EBITDA | -$32.81M | -$34.06M | -$44.02M | -$38.36M | -$18.76M | -$16.84M | -$16.89M | -$15.20M |
| EPS (basic) | -0.99 | -1.02 | -1.32 | — | -0.59 | -0.53 | -0.53 | — |
| EPS (diluted) | -0.99 | -1.02 | -1.32 | — | -0.59 | -0.53 | -0.53 | — |
| Weighted avg. shares (diluted) | 31.42M | 31.37M | 31.35M | — | 28.54M | 28.08M | 27.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30.55M | $24.21M | $24.77M | $25.18M | $25.40M | $37.61M | $23.04M | $20.16M |
| Receivables | $913,000 | $442,000 | $343,000 | $329,000 | — | — | — | $0 |
| Inventory | $4.76M | $4.12M | $3.50M | $2.94M | $949,000 | — | — | $0 |
| Current assets | $206.90M | $233.28M | $268.37M | $301.41M | $207.00M | $213.60M | $197.86M | $211.92M |
| PP&E, net | $640,000 | $1.00M | $1.10M | $1.19M | $1.26M | $1.17M | $926,000 | $651,000 |
| Total assets | $209.75M | $236.60M | $272.54M | $305.88M | $210.70M | $217.33M | $201.25M | $215.30M |
| Current liabilities | $17.75M | $17.21M | $25.81M | $21.19M | $16.32M | $10.40M | $8.57M | $10.41M |
| Total liabilities | $17.75M | $17.33M | $26.04M | $21.54M | $16.78M | $10.97M | $9.24M | $11.22M |
| Shareholders' equity | $192.00M | $219.26M | $246.49M | $284.34M | $193.93M | $206.37M | $192.01M | $204.08M |
| Shares outstanding | 31.42M | 31.42M | 31.35M | 31.34M | 28.59M | 28.50M | 27.54M | 27.52M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.31M | -$38.71M | -$33.58M | -$33.02M | -$8.59M | -$11.51M | -$16.05M | -$9.08M |
| Capital expenditure | $0 | $16,000 | $18,000 | $38,000 | $439,000 | $240,000 | $110,000 | $149,000 |
| Free cash flow | -$22.31M | -$38.73M | -$33.60M | -$33.06M | -$9.03M | -$11.75M | -$16.16M | -$9.23M |
| Investing cash flow | $28.66M | $37.75M | $33.16M | -$89.81M | -$4.33M | -$414,000 | $18.89M | -$11.86M |
| Financing cash flow | $0 | $395,000 | $14,000 | $122.61M | $598,000 | $26.49M | $44,000 | $53,000 |
| Depreciation & amortization | $109,000 | $110,000 | $111,000 | $107,000 | $125,000 | $19,000 | $36,000 | $25,000 |
| Stock-based compensation | $4.13M | $4.47M | $4.32M | $3.68M | $3.47M | $2.85M | $2.56M | $1.63M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.